Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer

Korean Journal of Radiology

Volumn 15, Issue 4, 2014, Pages 411-422

  Jang, Mijung ^a   Yoon, Young Il ^b   Kwon, Yong Soo ^c   Yoon, Tae Jong ^b,c   Lee, Hak Jong ^a,b   Hwang, Sung Il ^a   Yun, Bo La ^a   Kim, Sun Mi ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c CHA University   (South Korea)

Author keywords

Breast cancer; Drug delivery; Iron oxide nanoparticles; Magnetic resonance imaging; Trastuzumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCENT MAGNETIC NANOPARTICLE; LIPOSOME; MAGNETIC NANOPARTICLE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BREAST CANCER; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCTIVELY COUPLED PLASMA ATOMIC EMISSION SPECTROSCOPY; LIGHT SCATTERING; MOUSE; MTT ASSAY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

BREAST CANCER; DRUG DELIVERY; IRON OXIDE NANOPARTICLES; MAGNETIC RESONANCE IMAGING; TRASTUZUMAB;

3T3 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; FERRIC COMPOUNDS; HUMANS; LIPOSOMES; MAGNETITE NANOPARTICLES; MICE; MOLECULAR TARGETED THERAPY; NANOCONJUGATES; NANOPARTICLES; RECEPTOR, ERBB-2; SILICON DIOXIDE;

EID: 84904686751     PISSN: 12296929     EISSN: None     Source Type: Journal    
DOI: 10.3348/kjr.2014.15.4.411     Document Type: Article

References (34)

1. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 2006;24:3299-3308
2. Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, et al. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 2004;22:843-850
3. Rogers WJ, Basu P. Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging. Atherosclerosis 2005;178:67-73
4. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005;26:3995-4021
5. Schellenberger E, Schnorr J, Reutelingsperger C, Ungethum L, Meyer W, Taupitz M, et al. Linking proteins with anionic nanoparticles via protamine: ultrasmall protein-coupled probes for magnetic resonance imaging of apoptosis. Small 2008;4:225-230
6. Li Z, Tan B, Allix M, Cooper AI, Rosseinsky MJ. Direct coprecipitation route to monodisperse dual-functionalized magnetic iron oxide nanocrystals without size selection. Small 2008;4:231-239
7. Kim J, Kim HS, Lee N, Kim T, Kim H, Yu T, et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew Chem Int Ed Engl 2008;47:8438-8441
8. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008;60:1278-1288
9. Cao H, Gan J, Wang S, Xuan S, Wu Q, Li C, et al. Novel silicacoated iron-carbon composite particles and their targeting effect as a drug carrier. J Biomed Mater Res A 2008;86:671-677
10. Kim T, Momin E, Choi J, Yuan K, Zaidi H, Kim J, et al. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells. J Am Chem Soc 2011;133:2955-2961
11. Yoon TJ, Kim JS, Kim BG, Yu KN, Cho MH, Lee JK. Multifunctional nanoparticles possessing a "magnetic motor effect" for drug or gene delivery. Angew Chem Int Ed Engl 2005;44:1068-1071
12. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008;60:1252-1265
13. Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 2001;3:385-389
14. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
15. Chen TJ, Cheng TH, Chen CY, Hsu SC, Cheng TL, Liu GC, et al. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009;14:253-260
16. Hilger I, Leistner Y, Berndt A, Fritsche C, Haas KM, Kosmehl H, et al. Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol 2004;14:1124-1129
17. Tran TA, Ekblad T, Orlova A, Sandstrom M, Feldwisch J, Wennborg A, et al. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Bioconjug Chem 2008;19:2568-2576
18. Lee H, Yoon TJ, Figueiredo JL, Swirski FK, Weissleder R. Rapid detection and profiling of cancer cells in fine-needle aspirates. Proc Natl Acad Sci U S A 2009;106:12459-12464
19. Stanisic DI, Martin LB, Liu XQ, Jackson D, Cooper J, Good MF. Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination. Infect Immun 2003;71:5700-5713
20. Kim JS, Yoon TJ, Yu KN, Noh MS, Woo M, Kim BG, et al. Cellular uptake of magnetic nanoparticle is mediated through energy-dependent endocytosis in A549 cells. J Vet Sci 2006;7:321-326
21. Jain TK, Richey J, Strand M, Leslie-Pelecky DL, Flask CA, Labhasetwar V. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials 2008;29:4012-4021
22. Cheng HL, Stikov N, Ghugre NR, Wright GA. Practical medical applications of quantitative MR relaxometry. J Magn Reson Imaging 2012;36:805-824
23. Lee JE, Lee N, Kim T, Kim J, Hyeon T. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc Chem Res 2011;44:893-902
24. Casciaro S, Conversano F, Ragusa A, Malvindi MA, Franchini R, Greco A, et al. Optimal enhancement configuration of silica nanoparticles for ultrasound imaging and automatic detection at conventional diagnostic frequencies. Invest Radiol 2010;45:715-724
25. Napierska D, Thomassen LC, Rabolli V, Lison D, Gonzalez L, Kirsch-Volders M, et al. Size-dependent cytotoxicity of monodisperse silica nanoparticles in human endothelial cells. Small 2009;5:846-853
26. Fu C, Liu T, Li L, Liu H, Chen D, Tang F. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials 2013;34:2565-2575
27. Sung CK, Hong KA, Lin S, Lee Y, Cha J, Lee JK, et al. Dualmodal nanoprobes for imaging of mesenchymal stem cell transplant by MRI and fluorescence imaging. Korean J Radiol 2009;10:613-622
28. Bumb A, Regino CA, Egen JG, Bernardo M, Dobson PJ, Germain RN, et al. Trafficking of a dual-modality magnetic resonance and fluorescence imaging superparamagnetic iron oxide-based nanoprobe to lymph nodes. Mol Imaging Biol 2011;13:1163-1172
29. Lu CW, Hung Y, Hsiao JK, Yao M, Chung TH, Lin YS, et al. Bifunctional magnetic silica nanoparticles for highly efficient human stem cell labeling. Nano Lett 2007;7:149-154
30. Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005;5:1003-1008
31. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-284
32. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998;89:307-314
33. Merlin JL, Barberi-Heyob M, Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2- expressing human breast cancer cell lines. Ann Oncol 2002;13:1743-1748
34. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749